Renal Cell Carcinoma (RCC) Clinical Trials

Find Renal Cell Carcinoma (RCC) Clinical Trials Near You

68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Complex Cystic Renal Leision

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a prospective, single-center, single-arm, diagnostic phase 2 study aimed at evaluating the sensitivity and specificity of 68Ga-NYM096 PET/CT in detecting clear cell renal cell carcinoma (ccRCC) in patients with complex renal cysts who are scheduled for surgical resection. The study will use histopathological diagnosis as the reference standard to assess the diagnostic accuracy of 68Ga-NYM096 PET/CT in identifying ccRCC within operable complex renal cystic lesion. The findings will provide critical insights into the performance of 68Ga-NYM096 PET/CT as a non-invasive imaging tool for the preoperative detection of ccRCC in this patient population.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 y

• Presence of complex renal cyst (Bosniak category II or higher)

• Scheduled for surgical resection of renal mass (partial or total nephrectomy, open, laparoscopic, or robot-assisted technique)

• Expected survival of at least 3 months

• ECOG ≤ 2

• Written informed consent provided for participation in the trial

• In the opinion of investigator, willing and able to comply with required study procedures.

Locations
Other Locations
China
Peking Union Medical College
RECRUITING
Beijing
Contact Information
Primary
Li Huo, MD
huoli@pumch.cn
+86 18612672038
Backup
Wenjia Zhu, MD
zhuwenjia_pumc@163.com
+86 18614080164
Time Frame
Start Date: 2025-05-01
Estimated Completion Date: 2027-07-01
Participants
Target number of participants: 70
Treatments
Experimental: 68Ga-NYM096 PET/CT
Each patient will receive one dose of 68Ga-NYM096 by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
Related Therapeutic Areas
Sponsors
Leads: Peking Union Medical College Hospital

This content was sourced from clinicaltrials.gov